Then Chaudhry, a 35-year-old government consultant, discovered he could pay to leapfrog the long lines himself. He registered to take two doses of the Russian-made Sputnik V vaccine for about $80 from a private hospital. That’s a lot of money in a country where the average worker makes about $110 per month, but Chaudhry was ready to make the commitment.
Critics have assailed such private sales in Pakistan and around the world, saying that they make inoculations available only to the wealthy. But in Pakistan, like elsewhere, tight supplies have stymied those efforts. The private hospitals are out of supplies, and Chaudhry still hasn’t been vaccinated.
“I am willing to pay double the price for the vaccine, but I don’t want to wait on and on,” Chaudhry said.
Access to the coronavirus vaccine has thrown a stark light on global inequality. The United States and other rich countries have bought up most of the world’s vaccine supplies to protect their own people, leaving millions of doses stockpiled and in some places unused. Less developed countries scramble over what’s left.
To speed up vaccinations, some countries have allowed doses to be sold privately. But those campaigns have been troubled by supply issues and by complaints that they simply reflect the global disparities.
“The Pakistani example is a microcosm of what has gone wrong with the global response — where wealth alone has primarily shaped who gets access,” Zain Rizvi, an expert on medicine access at Public Citizen, a Washington, D.C., advocacy group, said in an email. “Ending the pandemic will require the global community to do much more than just that.”
Pakistan’s need is growing. The country of nearly 220 million people is reporting more than 2,500 new infections a day, but its low rate of testing suggests many more cases remain undetected. The government has toughened restrictions and limited public gatherings.